Mooli Ravi K, Sadasivam Kalaimaran
Kanchi Kamakoti CHILDS Trust Hospital, Chennai, Tamil Nadu, India.
Glob Pediatr Health. 2021 May 31;8:2333794X211022250. doi: 10.1177/2333794X211022250. eCollection 2021.
Many children needing pediatric intensive care units care require inotropes, which are started peripherally prior to securing a central venous access. However, many hospitals in low- and middle-income countries (LMIC) may not have access to central lines and the vasoactive medications are frequently given through a peripheral venous access. : The aim of our study was to describe the role of peripheral vasoactive inotropes in children. : Children requiring peripheral vasoactive medications were included in this study. We retrospectively collected data at 2 time points on use and complications of peripheral vasoactive medications. : Eighty-four children (51 pre-COVID era and 33 COVID pandemic) received peripheral vasoactive medications. Only 3% of children (3/84) developed extravasation injury, all of whom recovered completely. : Results from our study suggest that extravasation injury due to peripheral inotrope infusion is very low (3%) and it may be safely administered in children at a diluted concentration.
许多需要儿科重症监护病房护理的儿童需要使用血管活性药物，这些药物在获得中心静脉通路之前先通过外周静脉给药。然而，低收入和中等收入国家（LMIC）的许多医院可能无法进行中心静脉置管，血管活性药物常常通过外周静脉通路给药。本研究的目的是描述外周血管活性药物在儿童中的作用。本研究纳入了需要使用外周血管活性药物的儿童。我们回顾性收集了两个时间点关于外周血管活性药物使用及并发症的数据。84名儿童（51名在新冠疫情前时期，33名在新冠疫情期间）接受了外周血管活性药物治疗。只有3%的儿童（3/84）发生了外渗损伤，所有患儿均完全康复。我们的研究结果表明，外周输注血管活性药物引起的外渗损伤非常低（3%），以稀释浓度给药对儿童可能是安全的。
